Daewon Pharmaceutical Codaewon SㆍBoryung Pharmaceutical Akarb, the stars in the first half

Daewon Pharmaceutical’s Codaewon S recorded the highest number of prescriptions in the first half among new drugs in the outpatient prescription market.

A total of 11 new drugs listed in the outpatient prescription market since the second half of last year have achieved more than 1 billion won in the first half, according to the UBIST.

Codaewon S recorded prescription sales of 3.7 billion won during the first half of the year and was the only drug to exceed 3 billion won.

Following Codaewon S, Akarb (Boryung Pharmaceutical) made 2.9 billion won in prescription sales and ranked 2nd by nearly double the third place. 

Selebeta     (Chong Kun Dang Pharmaceutical) and Choline Max (Cosmax Pharma) both surpassed 1.5 billion won with 1.6 billion won.

Then, Newstazet R (Samjin Pharmaceutical) and Tamsuall (Dasan Pharmaceutical) followed with 1.3 billion won, and Diqualon (Reyon Pharmaceutical) with 1.2 billion won.

L50 (Boryung Pharmaceutical), Rosu Duo (Cires Pharmaceutical), Kisqali (Novartis), and Atmeg Combigel (Korea United Pharm) recorded 1.1 billion won prescription sales. 

Meanwhile, nearly half of the 11 items, including Akarb, Newstazet R, L50, Rosu Duo, and Atmeg Combigel, are statin combination drugs, showing dyslipidemia combination therapy is still growing.